Zolgensma denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Zolgensma Under a Quantity Limit

Zolgensma (onasemnogene abeparvovec) is a one-time, single-dose gene therapy for spinal muscular atrophy (SMA). A quantity-limit denial in this context is unusual — because the therapy is designed to be administered once — but it can arise in a few specific situations: the insurer may flag the request as exceeding what the FDA-approved prescribing label authorizes for this patient's weight or age range, the plan may have a policy that technically limits gene therapies to one lifetime authorization (which may create a barrier if any prior SMA gene therapy claim exists on the account), or a billing/coding issue may cause the system to interpret the claim as a duplicate or excess quantity.

Identifying the exact reason for the quantity-limit flag is the essential first step. Request the full explanation of benefits and the specific policy language that triggered the limit.

## Your Appeal Rights

• Internal appeal: File a written internal appeal within the timeframe stated on the denial notice. Under ERISA §503, employer-plan members are entitled to a full-and-fair review and access to all criteria the plan applied.
• External review (ACA §2719): After an adverse internal decision, you have the right to independent external review, typically within a four-month window from the final denial. For urgent or rapidly progressing disease, request expedited external review (72-hour turnaround required).

## Documentation to Gather

1. FDA prescribing label — obtain the current label from fda.gov and identify the authorized dosing and administration structure; confirm the requested quantity is consistent with the label. 2. Genetic confirmation and diagnosis — laboratory report confirming SMA with SMN1 and SMN2 copy number analysis. 3. Body weight and clinical measurements — dated chart records showing the patient's current weight and relevant clinical parameters, to confirm the requested administration is within label parameters. 4. Treatment history — confirmation that no prior Zolgensma administration has occurred (ruling out a true duplicate), or if a prior administration did occur, the clinical rationale documented by the neurologist. 5. Prescriber letter — the treating neurologist should confirm that the requested quantity is consistent with the FDA-approved label and the patient's clinical profile. 6. Billing/coding review — have the specialty pharmacy or infusion center verify that the claim codes correctly represent a single-administration gene therapy.

## Criteria-Mapping Structure

Request UnitedHealthcare's quantity-limit policy for Zolgensma. Map each stated basis for the limit to your documentation:

| Limit Basis | Rebuttal Documentation | |---|---| | Quantity authorized per FDA label | FDA label excerpt showing single-dose structure | | Patient weight / clinical parameters | Chart measurement with date | | No prior Zolgensma administration | Treatment history log | | Correct coding for single gene therapy administration | Billing team confirmation |

If the quantity limit is the result of a billing or coding error, resolution through a corrected claim may be faster than a formal appeal. If the limit reflects a genuine policy restriction inconsistent with the FDA label, the appeal should center on the argument that the plan cannot impose quantity limits more restrictive than the label without a specific, published clinical rationale — a point that external reviewers frequently find compelling.